Prime Lab LLC failed U.S. drug manufacturing quality rules for over-the-counter hand soaps and sanitizers, including raw-material testing and shared toxic equipment.
What happened
FDA inspected Prime Lab’s Ponce, Puerto Rico drug manufacturing facility from July 31 to August 4, 2023. Investigators found the firm made over-the-counter antibacterial hand soap and hand sanitizer without adequate raw-material identity testing, cleaned equipment inadequately, and used the same equipment for toxic industrial detergents and disinfectants. FDA reviewed the firm’s August 24, 2023 response and found it inadequate.
What FDA found
The firm did not test each incoming raw material lot for identity and did not establish that supplier test results were reliable.
21 CFR 211.84(d)(1) and 211.84(d)(2)The firm lacked adequate written cleaning and maintenance procedures; equipment cleaning was rinsing with water and using rags for an unspecified time.
21 CFR 211.67(b)The firm used the same equipment for drug products and toxic industrial detergents and disinfectants, risking cross-contamination.
21 CFR 211.67(b)The firm did not routinely calibrate equipment or perform preventive maintenance.
21 CFR 211.67(b)The firm’s quality oversight group did not adequately oversee drug manufacturing, including finished-product testing, water-system monitoring, and stability-supported expiration dates.
21 CFR 211.22(a) and 211.22(d); 211.165(a); 211.100(a); 211.192; 211.137(a)
What FDA wants
FDA tells Prime Lab to respond in writing within 15 working days and to provide extensive corrections, including diethylene glycol and ethylene glycol test results within 30 calendar days, risk assessments, cleaning and quality oversight remediation, and notification before resuming drug manufacturing.
Who should pay attention
- retailers and distributors selling Prime Lab over-the-counter hand soaps or sanitizers
- brands or contractors using Prime Lab as a drug manufacturer
- consumers using over-the-counter antibacterial hand soap or hand sanitizer
This is a summary. Read the original letter on fda.gov.